TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31667338

Group type: EXPERIMENTAL
Intervention: Letrozole + Dasatinib (100 mg/day PO)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Letrozole (2.5 mg/day PO)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Crossover to Letrozole + Dasatinib
Number of subjects: 120
Study: 30742373

Group type: EXPERIMENTAL
Intervention: Imidafenacin 0.1 mg, twice a day for 12 weeks
Number of subjects: 296

Group type: COMPARATOR
Intervention: Tolterodine 2 mg, twice a day for 12 weeks
Number of subjects: 296
Study: 27514861

Group type: EXPERIMENTAL
Intervention: Standard port location (Task A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified port location (Task B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group I (Task A → Task B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group II (Task B → Task A)
Number of subjects: 0
Study: 24129806

Group type: EXPERIMENTAL
Intervention: Enhanced REP
Number of subjects: 384

Group type: COMPARATOR
Intervention: Standard REP
Number of subjects: 384
Study: 22520132

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV), RotaTeq(®), 3 doses at 6, 10, and 14 weeks of age
Number of subjects: 6674

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV), RotaTeq(®)
Number of subjects: 6674
Study: 20177759

Group type: EXPERIMENTAL
Intervention: Bundle ablation approach (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional anatomical approach (Group 1)
Number of subjects: 60
Study: 18664319

Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 4983
Study: 15914134

Group type: EXPERIMENTAL
Intervention: ACIDFORM gel (2 mL applied at bedtime for 7 consecutive days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: K-Y Jelly Personal Lubricant (control group)
Number of subjects: 36
Study: 11823086

Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient management program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (nonintervention group)
Number of subjects: 200
Study: 9614476

Group type: EXPERIMENTAL
Intervention: Self-exposure treatment
Number of subjects: 170

Group type: COMPARATOR
Intervention: Self-relaxation treatment
Number of subjects: 170

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 170
Study: 8714922

Group type: EXPERIMENTAL
Intervention: 2-hour/8-hour clinical groups
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 5-hour/5-hour clinical groups
Number of subjects: 93

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 93
Study: 2527971

Group type: EXPERIMENTAL
Intervention: Toremifene (doses of 20 to 400 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unbound plasma toremifene and its metabolites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxorubicin (in the presence of toremifene)
Number of subjects: 0
Study: 7588

Group type: EXPERIMENTAL
Intervention: Piperacetazine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thioridazine
Number of subjects: 50
Study: 31190607

Group type: EXPERIMENTAL
Intervention: Deep learning based on fully convolutional neural network (FCNN) for segmenting brain tissues including T2-hyperintense MS lesions.
Number of subjects: 1000
Study: 27043224

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg, t.i.d.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glibenclamide (5 mg, t.i.d.)
Number of subjects: 50
Study: 25927692

Group type: EXPERIMENTAL
Intervention: Ad-hoc tailored nursing intervention providing information and emotional support
Number of subjects: 436

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Ad-hoc tailored nursing intervention
Number of subjects: 436
Study: 23204049

Group type: EXPERIMENTAL
Intervention: Familial probands with IAs
Number of subjects: 323
Study: 21897774

Group type: EXPERIMENTAL
Intervention: Active treatment with position monitoring and supine alarm device
Number of subjects: 15

Group type: COMPARATOR
Intervention: Inactive treatment (control)
Number of subjects: 15
Study: 19567759

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study: 16485885

Group type: EXPERIMENTAL
Intervention: Various treatment modalities including chemopreventative, chemotherapeutic, destructive, and novel immunologic methods.
Number of subjects: 0
Study: 15110128

Group type: COMPARATOR
Intervention: Statin use (lovastatin or pravastatin)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Statin use
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 6
Study: 10931021

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open fundoplication
Number of subjects: 60
Study: 9762211

Group type: EXPERIMENTAL
Intervention: Early feeding (Group A): milk on day 1, mixed warm feeding on day 2, normal diet from day 3.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nil by mouth until day 3 (Group B): milk on day 4, mixed warm feeding on day 5, normal diet from day 6.
Number of subjects: 26
Study: 7824563

Group type: EXPERIMENTAL
Intervention: Thermoneutral water temperature
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preferred water temperature
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Slow thermal changes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rapid thermal changes
Number of subjects: 30
Study: 3293873

Group type: EXPERIMENTAL
Intervention: 0.125 mg trimoprostil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.75 mg trimoprostil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3.0 mg trimoprostil
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31882016

Group type: COMPARATOR
Intervention: Acupuncture treatment at 11 local and 4 distal acupuncture points for 20 min twice a week for 6 weeks (Control Group)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at 11 local and 4 distal acupuncture points for 20 min twice a week for 6 weeks + Palmijihwang‐hwan for 6 weeks (Treatment Group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Treatment Group
Number of subjects: 84
Study: 29291695

Group type: EXPERIMENTAL
Intervention: Evidence-based therapy delivered by trained frontline workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training and implementation of evidence-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crisis management responsibilities of case managers
Number of subjects: 0
Study: 27515749

Group type: EXPERIMENTAL
Intervention: Higher neighbourhood socioeconomic position (NSEP) among non-diabetics
Number of subjects: 1789

Group type: EXPERIMENTAL
Intervention: Higher neighbourhood socioeconomic position (NSEP) among pre-diabetics
Number of subjects: 1789
Study: 24997748

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections, 2 injections during the first 2 weeks after injury.
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (historical control from a randomized trial with nonoperative treatment).
Number of subjects: 145
Study: 23083956

Group type: EXPERIMENTAL
Intervention: Maxillary distraction osteogenesis (DO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional orthognathic surgery (CO)
Number of subjects: 0
Study: 19454638

Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of 100 x 10(6) autologous bone marrow‐derived mononuclear cells
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 50
Study: 17197401

Group type: EXPERIMENTAL
Intervention: Chemo-mechanical caries removal (CMCR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional method (TM)
Number of subjects: 50
Study: 16022846

Group type: EXPERIMENTAL
Intervention: 4x400 microg po every 3 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2x800 microg po every 6 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1x600 pv microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2x800 microg po every 3 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1x800 pv microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 800 microg pv wetted with saline repeated after 24 h if intact gestational sac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2x800 microg pv wetted with saline
Number of subjects: 0
Study: 12238641

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 30
Study: 10443645

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment for 10 years
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 21
Study: 7805238

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg TID)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 35% O2 administration
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High altitude exposure
Number of subjects: 22
Study: 2129678

Group type: EXPERIMENTAL
Intervention: Health education course consisting of 3 informative-participative sessions
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 98
Study: 478632

Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccine (H3ChN2Ch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccine (Heq1N2Ch)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7043175

Group type: COMPARATOR
Intervention: Clopamide (5 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Clopamide (5 mg/day) + Pindolol (10 mg/day)
Number of subjects: 17
Study: 31961417

Group type: EXPERIMENTAL
Intervention: Lotion sunscreen
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aerosol spray sunscreen
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nonaerosol spray sunscreen
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pump spray sunscreen
Number of subjects: 48
Study: 31764094

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 33
Study: 27556931

Group type: EXPERIMENTAL
Intervention: Home Care Package Program for Relieving Hiesho (self-care program including wearing leg warmers, performing exercises, and pressing acupuncture points for 4 weeks)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no specific actions taken)
Number of subjects: 140
Study: 25622917

Group type: EXPERIMENTAL
Intervention: Conscious awareness of disgust images
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal awareness of disgust images
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral images in conscious condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disgust images in conscious condition
Number of subjects: 0
Study: 24439628

Group type: EXPERIMENTAL
Intervention: Aspheric lenses (Medalist Fresh fit (PUREVISION 2 HD); Bausch+Lomb)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Spherical lenses (ACUVUE Oasys; Johnson & Johnson)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Comparison of spherical and aspheric lenses at different powers
Number of subjects: 11
Study: 22368035

Group type: EXPERIMENTAL
Intervention: Mnemonic strategy training (MS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched-exposure control group (XP)
Number of subjects: 0
Study: 19188394

Group type: EXPERIMENTAL
Intervention: High-dose cefepime, 2 g every 8 h (3-h infusion)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Model validation group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Initial model
Number of subjects: 32
Study: 17898243

Group type: EXPERIMENTAL
Intervention: Contextual variant of cases
Number of subjects: 54

Group type: COMPARATOR
Intervention: Baseline variant of cases
Number of subjects: 54
Study: 14691438

Group type: EXPERIMENTAL
Intervention: Carriership of the PlA2 allele in the highest fibrinogen quartile
Number of subjects: 455
Study: 11802750

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg 4 times a day)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Lansoprazole (15 mg once daily)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Active treatment groups (misoprostol and lansoprazole)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 537
Study: 11072388

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 10
Study: 8772218

Group type: EXPERIMENTAL
Intervention: Gelatin as prime in the heart-lung machine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose of gelatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-aprotinin patients
Number of subjects: 60
Study: 2209907

Group type: EXPERIMENTAL
Intervention: Peribulbar anaesthesia
Number of subjects: 99

Group type: COMPARATOR
Intervention: Retrobulbar anaesthesia
Number of subjects: 99
Study: 7001056

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29786964

Group type: EXPERIMENTAL
Intervention: Laquinimod 0.6 mg/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Laquinimod 1.2 mg/day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg on day 14
Number of subjects: 200
Study: 27790791

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) with 2 mA anodal tDCS over DLPFC
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CBM with active stimulation during training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham stimulation during training
Number of subjects: 100
Study: 25573150

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with goniosynechialysis (PE+GSL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Phacoemulsification alone (PE)
Number of subjects: 22
Study: 23413906

Group type: EXPERIMENTAL
Intervention: Thymopetidum (20 mg intramuscular injection, once every other day for 3 months)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Regular therapy (control group)
Number of subjects: 156
Study: 20938778

Group type: EXPERIMENTAL
Intervention: Inulin-enriched pasta
Number of subjects: 20
Study: 19807760

Group type: EXPERIMENTAL
Intervention: Small-particle NASHA gel
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Large-particle NASHA gel
Number of subjects: 150

Group type: COMPARATOR
Intervention: Both NASHA fillers (small and large particle)
Number of subjects: 150
Study: 17325686

Group type: EXPERIMENTAL
Intervention: Glucose drink (75 g/300 ml)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Noncaloric sweetened drink
Number of subjects: 65
Study: 15052514

Group type: EXPERIMENTAL
Intervention: Atypical neuroleptics
Number of subjects: 86439

Group type: COMPARATOR
Intervention: Typical neuroleptics
Number of subjects: 86439
Study: 11848167

Group type: EXPERIMENTAL
Intervention: Regular alcohol consumption (mean daily intake of 66.5 ± 4.7 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alcohol restriction (mean daily intake of 10.2 ± 1.9 ml)
Number of subjects: 30
Study: 10607247

Group type: EXPERIMENTAL
Intervention: Daily IFN-alpha (3 MU daily for 3 months followed by t.i.w. for 3 months)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Thrice weekly IFN-alpha (3 MU t.i.w. for 6 months)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Daily IFN-alpha
Number of subjects: 149

Group type: COMPARATOR
Intervention: Thrice weekly IFN-alpha
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Daily IFN-alpha (for patients infected with HCV types other than HCV-1)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Thrice weekly IFN-alpha (for patients infected with HCV types other than HCV-1)
Number of subjects: 149
Study: 7853632

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori infection
Number of subjects: 45
Study: 2313000

Group type: EXPERIMENTAL
Intervention: Long-term exercise group (Group A, n = 80)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Short-term exercise group (Group B, n = 42)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Contract control group (Group C, n = 62)
Number of subjects: 184
Study: 7352857

Group type: EXPERIMENTAL
Intervention: 20 microL of 0.5% pilocarpine hydrochloride
Number of subjects: 10

Group type: COMPARATOR
Intervention: 50 microL of 0.5% pilocarpine hydrochloride
Number of subjects: 10
Study: 31840162

Group type: EXPERIMENTAL
Intervention: Whole apple (WA) consumption
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control beverage (CB)
Number of subjects: 40
Study: 29789393

Group type: EXPERIMENTAL
Intervention: Intravenous glyburide
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 26696273

Group type: EXPERIMENTAL
Intervention: Unflavoured e-liquid (UF2.0%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flavoured e-liquid (FL2.0%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine inhalator (Nicorette(®); 15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cigarette (CC; JPS Silver King Size, 0.6 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVP with 0% nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVP with 0.4% nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVP with 0.9% nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVP with 2.0% nicotine
Number of subjects: 0
Study: 25317990

Group type: EXPERIMENTAL
Intervention: Electric field-induced release and measurement (EFIRM) for saliva-based EGFR mutation detection
Number of subjects: 62
Study: 22228146

Group type: EXPERIMENTAL
Intervention: Organized screening with annual PSA testing for 6 years and annual DRE for 4 years (intervention arm)
Number of subjects: 76885

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 76885

Group type: EXPERIMENTAL
Intervention: Both intervention and control arms
Number of subjects: 76885
Study: 20938948

Group type: EXPERIMENTAL
Intervention: Nasal packs with airways
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Totally occluding nasal packs
Number of subjects: 39

Group type: COMPARATOR
Intervention: Both groups (Nasal packs with airways and Totally occluding nasal packs)
Number of subjects: 39
Study: 18557715

Group type: EXPERIMENTAL
Intervention: Noradrenaline 0.5-3.0 mg/h and albumin (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Terlipressin 0.5-2 mg, 6 hourly and albumin (group B)
Number of subjects: 40
Study: 16075193

Group type: EXPERIMENTAL
Intervention: Nurse Family Partnership (NFP) - home visitation by registered nurses pre‐ and postnatally
Number of subjects: 324

Group type: COMPARATOR
Intervention: No visitation (Control)
Number of subjects: 324
Study: 11934087

Group type: EXPERIMENTAL
Intervention: Web-based assessment techniques
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Web-based with interruption (Web-I)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Paper-based (P&P)
Number of subjects: 255
Study: 10462251

Group type: EXPERIMENTAL
Intervention: Vaccine containing three recombinant malaria antigens (MSP1 190LCS.T3, MSP2, RESA) with Montanide ISA720 adjuvant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture of antigens
Number of subjects: 0

Group type: COMPARATOR
Intervention: MSP2 with Montanide ISA720
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injection of antigens
Number of subjects: 0
Study: 9050705

Group type: EXPERIMENTAL
Intervention: Topical anesthesia with 2% mepivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 42
Study: 1860020

Group type: EXPERIMENTAL
Intervention: 5 mg fluphenazine decanoate every two weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg fluphenazine decanoate every two weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg fluphenazine decanoate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluphenazine plasma levels
Number of subjects: 0
Study: 6352119

Group type: EXPERIMENTAL
Intervention: Oxprenolol once daily (160-480 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Oxprenolol twice daily (160-480 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Oxprenolol once daily
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Oxprenolol twice daily
Number of subjects: 175
Study: 31021358

Group type: EXPERIMENTAL
Intervention: Essential Amino Acids (EAA)-based multi-ingredient nutritional supplement
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 38
Study: 30235653

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (specifics not provided)
Number of subjects: 371
Study: 26774907

Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose (SMBG) regimen
Number of subjects: 820
Study: 24571588

Group type: EXPERIMENTAL
Intervention: Combined IHC parameters
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined PET/IHC characteristics
Number of subjects: 14
Study: 21920481

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 20548096

Group type: EXPERIMENTAL
Intervention: R-CHOP therapy (rituximab plus CHOP)
Number of subjects: 399

Group type: COMPARATOR
Intervention: CHOP therapy (standard CHOP chemotherapy)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Both R-CHOP and CHOP
Number of subjects: 399
Study: 17604557

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Number of subjects: 135

Group type: COMPARATOR
Intervention: Sham acupuncture (using the Streitberger placebo needle)
Number of subjects: 135
Study: 16083541

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 1124
Study: 12372444

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b
Number of subjects: 52

Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: GnRH analogs depot
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Oral indomethacin
Number of subjects: 52